Adynxx Inc
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-… Read more
Adynxx Inc (ADYX) - Total Assets
Latest total assets as of September 2019: $3.25 Million USD
Based on the latest financial reports, Adynxx Inc (ADYX) holds total assets worth $3.25 Million USD as of September 2019.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Adynxx Inc - Total Assets Trend (1999–2018)
This chart illustrates how Adynxx Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Adynxx Inc - Asset Composition Analysis
Current Asset Composition (December 2018)
Adynxx Inc's total assets of $3.25 Million consist of 96.1% current assets and 3.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.8% |
| Accounts Receivable | $34.00K | 0.4% |
| Inventory | $101.00K | 1.0% |
| Property, Plant & Equipment | $10.00K | 0.1% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2018)
This chart illustrates how Adynxx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adynxx Inc's current assets represent 96.1% of total assets in 2018, a decrease from 98.4% in 1999.
- Cash Position: Cash and equivalents constituted 91.8% of total assets in 2018, down from 98.3% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is inventory at 1.0% of total assets.
Adynxx Inc Competitors by Total Assets
Key competitors of Adynxx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Adynxx Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Adynxx Inc generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Adynxx Inc is currently not profitable relative to its asset base.
Adynxx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.18 | 3.95 | 4.75 |
| Quick Ratio | 0.18 | 3.89 | 4.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-11.25 Million | $ 9.14 Million | $ 15.50 Million |
Adynxx Inc - Advanced Valuation Insights
This section examines the relationship between Adynxx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -70.6% |
| Total Assets | $9.68 Million |
| Market Capitalization | $102.99 USD |
Valuation Analysis
Below Book Valuation: The market values Adynxx Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Adynxx Inc's assets decreased by 70.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adynxx Inc (1999–2018)
The table below shows the annual total assets of Adynxx Inc from 1999 to 2018.
| Year | Total Assets | Change |
|---|---|---|
| 2018-12-31 | $9.68 Million | -70.62% |
| 2017-12-31 | $32.94 Million | -39.56% |
| 2016-12-31 | $54.50 Million | -39.28% |
| 2015-12-31 | $89.75 Million | +201.95% |
| 2014-12-31 | $29.72 Million | +70.32% |
| 2013-12-31 | $17.45 Million | +27.13% |
| 2012-12-31 | $13.73 Million | -2.12% |
| 2011-12-31 | $14.03 Million | -44.34% |
| 2010-12-31 | $25.20 Million | +275.54% |
| 2009-12-31 | $6.71 Million | +110.81% |
| 2008-12-31 | $3.18 Million | +281.15% |
| 2007-12-31 | $835.06K | +198.32% |
| 2006-12-31 | $279.92K | +147.86% |
| 2005-12-31 | $112.94K | -81.62% |
| 2004-12-31 | $614.35K | +96.78% |
| 2003-12-31 | $312.20K | +969.73% |
| 2002-12-31 | $29.18K | -78.92% |
| 2001-12-31 | $138.47K | -10.42% |
| 2000-12-31 | $154.58K | -16.45% |
| 1999-12-31 | $185.01K | -- |